---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-134854"
form_type: "8-K"
ticker: "KOD"
cik: "0001468748"
company_name: "Kodiak Sciences Inc."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:08:44.526328+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kodiak reports positive Phase 3 GLOW2 data for Zenkuda; plans accelerated BLA

## Summary
- Zenkuda Phase 3 GLOW2: 62.5% vs 3.3% achieved ≥2-step DRSS improvement (p<0.0001).
- 85% risk reduction in sight-threatening complications (2.4% vs 15.8%, p=0.0001); no intraocular inflammation.
- DAYBREAK Phase 3 wet AMD study fully enrolled (690 subjects); topline expected Sept 2026.
- Q4 2025 net loss $56.7M ($1.04/shr); cash $209.9M; Dec 2025 equity raise net $173M.
- KSI-101 Phase 3 PEAK topline 4Q2026, PINNACLE 2Q2027; Phase 1b APEX data showed robust responses.

## SEC filing metadata
- accession: 0001193125-26-134854
- form_type: 8-K
- ticker: KOD
- cik: 0001468748
- company_name: Kodiak Sciences Inc.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468748/000119312526134854/0001193125-26-134854-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468748/000119312526134854/kod-20260331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-134854
- JSON: https://secwatch.observer/filing/0001193125-26-134854.json
- Plain text: https://secwatch.observer/filing/0001193125-26-134854.txt

## Key facts
- Earnings Releases
  Kodiak Sciences Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss for the fourth quarter of 2025 was $56.7 million, or $1.04 per share on both a basic and diluted basis.
  - Period: the fourth quarter and full year ended December 31, 2025
  - Net income: Net loss for the fourth quarter of 2025 was $56.7 million, or $1.04 per share on both a basic and diluted basis
  - Result: reported results
  source text: On March 31, 2026, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the quarter and year ended December 31, 2025 and business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1468748/000119312526134854/0001193125-26-134854-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.